Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex®) after prior progestin and anastrozole therapy

Gynecologic Oncology

Volumn 100, Issue 2, 2006, Pages 439-441

  Hoffman, M A ^a   Khan, A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Aromatase inhibitors; Endometrial carcinoma; Fulvestrant; Hormonal therapy; Progestins

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; FULVESTRANT; GESTAGEN; MEGESTROL ACETATE; PROGESTERONE RECEPTOR;

ADENOCARCINOMA; AGED; ANAMNESIS; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG METASTASIS; LYMPHADENOPATHY; PRIORITY JOURNAL; REMISSION; SALPINGOOOPHORECTOMY; VAGINA CANCER;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; LUNG NEOPLASMS; NITRILES; PROGESTINS; TRIAZOLES;

EID: 30444432701     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.09.011     Document Type: Article

References (10)

1. A. Kauppila Progestin therapy of endometrial, breast and ovarian carcinoma Acta Obstet. Gynecol. Scand. 63 1984 441 450
2. M. Baekelandt Hormonal treatment of endometrial carcinoma Expert Rev. Anticancer Ther. 2 2002 106 112
3. L.B. Michaud Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer AJHP 62 2005 266 273
4. P.G. Rose, V.L. Brunetto, and J. Bell A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology study Gynecol. Oncol. 78 2000 212 216
5. B.B. Ma, A. Oza, E. Eisenhauer, G. Stanimir, M. Carey, and W. Chapman The activity of letrozole in patients with advanced or recurrent endometrial carcinoma and correlation with biological markers-A study of the National Cancer Institute of Canada Clinical Trials Group Int. J. Gynecol. Cancer 4 2004 650 658
6. A.E. Wakeling, M. Dukes, and J. Bowler A potent specific pure antiestrogen with clinical potential Cancer Res. 51 1991 3867 3873
7. A. Howell, C.K. Osborne, C. Morris, and A.E. Wakeling ICI 182,780 (Faslodex®). Development of a novel, "pure" antiestrogen Cancer 89 2000 817 825
8. J. Robertson Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer Clin. Ther. 24 Suppl A 2002 17 30
9. J.F.R. Robertson, S.E. Come, S.E. Jones, L. Beex, M. Kaufmann, and A. Makris Endocrine treatment options for advanced breast cancer-The role of fulvestrant Eur. J. Cancer 41 2005 346 356
10. R.M. O'Regan, A. Cisneros, G. England, J.I. MacGregor, H.D. Muenczner, and V.J. Assikis Effects of the antiestrogens tamoxifen, toremifine, and ICI 182,780 on endometrial cancer growth JNCI 90 1998 1552 1558